Aripiprazole in Treatment-Refractory Schizophrenia

被引：3

作者：

Hsu, Wen-Yu ^{[1
]}

Lee, Chien-I ^{[1
]}

Chiu, Nan-Ying ^{[1
,3
]}

Kahn, David A. ^{[2
]}

机构：

[1] Changhua Christian Hosp, Changhua, Taiwan

[2] Columbia Univ, Dept Psychiat, Changhua, Taiwan

[3] Chang Jung Christian Univ, Changhua, Taiwan

来源：

JOURNAL OF PSYCHIATRIC PRACTICE | 2009年 / 15卷 / 03期

关键词：

treatment-refractory schizophrenia; antipsychotics; clozapine; aripiprazole; TREATMENT-RESISTANT SCHIZOPHRENIA; CLOZAPINE-ASSOCIATED AGRANULOCYTOSIS; DOUBLE-BLIND; N-DESMETHYLCLOZAPINE; AUGMENTATION; ANTIPSYCHOTICS; EFFICACY; TRIAL; RISK;

D O I：

10.1097/01.pra.0000351883.75754.45

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Clozapine is the first choice antipsychotic medication for treatment-refractory schizophrenia; however, there are some disadvantages in using clozapine. A few reports have appeared concerning switching from clozapine to other antipsychotics for treatment-refractory schizophrenia. This report describes the case of a 58-year-old female patient with treatment-refractory schizophrenia who was successfully switched from clozapine 300 mg/day to aripiprazole 20 mg/day because of changes in consciousness. After the switch to aripiprazole, the patient's psychotic condition improved. As expected, we identified few successful cases of switches from clozapine in our search of the literature. Although controlled clinical trial data support use of clozapine in treatment-refractory schizophrenia, some patients cannot tolerate this agent or it may increase the risk of physical problems for some patients. In such situations, clinicians may want to consider prescribing a different antipsychotic or adding another antipsychotic and decreasing the dosage of clozapine. (Journal of Psychiatric Practice 2009;15:221-226)

引用

页码：221 / 226

页数：6

共 30 条

[1]

Andreasen N.C., 1984, The Scale for the Assessment of Positive Symptoms SAPS

[2] Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors:: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist [J].